Failure of tumor-reactive lymph node cells to kill tumor in the presence of immune-suppressive CD34+ cells can be overcome with vitamin D3 treatment to diminish CD34+ cell levels (original) (raw)

References

  1. Katz AE, 1993, Update on immunology of head and neck cancer. Med Clin N Am, 77, 625-31.
    PubMed Google Scholar
  2. Correa MR, Ochoa AC, Ghosh P, Mizoguchi H, Harvey L and Longo DL, 1997, Sequential development of structural and functional alterations in T cells from tumor-bearing mice. J Immunol, 158, 5292-6.
    PubMed Google Scholar
  3. Alexander JP, Kudoh S, Melsop KA, et al. 1993, T-cells infiltrating renal cell carcinoma display a poor proliferative response even though they can produce interleukin 2 and express interleukin 2 receptors. Cancer Res, 53, 1380-7.
    PubMed Google Scholar
  4. Wojtowiczpraga S, 1997, Reversal of tumor-induced immunosuppression: a new approach to cancer therapy. J Immunother, 20, 165-77.
    PubMed Google Scholar
  5. O’Mahony AM, O’Sullivan GC, O’Connell J, Cotter TG and Collins JK, 1993, An immune suppressive factor derived from esophageal squamous carcinoma induces apoptosis in normal and transformed cells of lymphoid lineage. J Immunol, 151, 4847-56.
    Google Scholar
  6. Hadden JW, Endicott J, Baekey P, Skipper P and Hadden EM, 1994, Interleukins and contrasuppression induce immune regression of head and neck cancer. Arch Otolaryngol Head Neck Surg, 120, 395-403.
    PubMed Google Scholar
  7. Wanebo HJ, Riley T, Karz D, Pace RC, Johns ME and Cantrell RW, 1988, Indomethacin sensitive suppressor-cell activity in head and neck cancer patients. The role of the adherent mononuclear cell. Cancer, 61, 462-74.
    PubMed Google Scholar
  8. Young MRI, Schmidt-Pak A, Wright MA, Matthews JP, Collins SL and Petruzzelli G, 1995, Mechanisms of immune suppression in patients with head and neck cancer: Presence of immune suppressive CD34+ cells in cancers that secrete granulocyte-macrophage colony-stimulating factor. Clin Cancer Res, 1, 95-103.
    PubMed Google Scholar
  9. Jaffe ML, Arai H and Nabel GJ, 1996, Mechanisms of tumor-induced immunosuppression: Evidence for contact-dependent T cell suppression by monocytes. Molecular Med, 2, 692-701.
    Google Scholar
  10. Sahasrabudhe DM and Dusel JC, 1994, Effect of murine interferon alpha/beta on tumour-induced suppressor function. Cancer Immunol Immunother, 39, 360-6.
    PubMed Google Scholar
  11. Gelber C, Eisenbach L, Feldman M and Goodenow RS, 1992, T-cell subset analysis of Lewis lung carcinoma tumor rejection: heterogeneity of effectors and evidence for negative regulatory lymphocytes correlating with metastasis. Cancer Res, 52, 6507-15.
    PubMed Google Scholar
  12. Subiza JL, Vinuela JE, Rodriguez R, Gil J, Figueredo MA and De la Concha EG, 1989, Development of splenic natural suppressor cells in Ehrlich tumor-bearing mice. Int J Cancer, 44, 307-17.
    PubMed Google Scholar
  13. Young MRI, Lozano Y, Ihm J, Wright MA and Prechel MM, 1996, Vitamin D3 treatment of tumor bearers can stimulate immune competence and reduce tumor growth when treatment coincides with a heightened presence of natural suppressor cells. Cancer Lett, 104, 153-61.
    Google Scholar
  14. Young MRI, Wright MA, Matthews JP, Malik I and Prechel M, 1996, Suppression of T cell proliferation by tumor-induced granulocyte-macrophage progenitor cells producing transforming growth factor-β and nitric oxide. J Immunol, 156, 1916-22.
    PubMed Google Scholar
  15. Brooks-Kaiser JC, Bourque LA and Hoskin DW, 1993, Heterogeneity of splenic natural suppressor cells induced in mice by treatment with cyclophosphamide. Immunopharmacology, 25, 117-29.
    Article PubMed Google Scholar
  16. Schmidt-Wolf IG, Dejbakhsh-Jones S, Ginzton N, Greenberg P and Strober S, 1992, T cell subsets and suppressor cells in human bone marrow. Blood, 80, 3242-50.
    PubMed Google Scholar
  17. Young MRI and Wright MA, 1992, Myelopoiesis-associated immune suppressor cells in mice bearing metastatic Lewis lung carcinoma tumors: interferon-??plus tumor necrosis factor-? synergistically reduce immune suppressor and tumor growth-promoting activities of bone marrow cells, and diminish tumor recurrence and metastasis. Cancer Res, 52, 6335-40.
    PubMed Google Scholar
  18. Field EH and Becker GC, 1992, Blocking of mixed lymphocyte reaction by spleen cells from total lymphoid-irradiated mice involves interruption of the IL-2 pathway. J Immunol, 148, 354-9.
    PubMed Google Scholar
  19. Moore SC, Theus SA, Barnett JB and Soderberg LS, 1992, Cytokine regulation of bone marrow natural suppressor cell activity in the suppression of lymphocyte function. Cell Immunol, 141, 398-408.
    PubMed Google Scholar
  20. Young MRI, Wright MA, Lozano Y, Matthews JP, Benefield J and Prechel MM, 1996, Mechanisms of immune suppression in patients with head and neck cancer: influence on the immune infiltrate of the cancer. Int J Cancer, 67, 333-8.
    PubMed Google Scholar
  21. Young MRI, Wright MA and Pandit R, 1997, Myeloid differentiation treatment to diminish the presence of immune suppressive CD34+ cells within human head and neck squamous cell carcinomas. J Immunol, 159, 990-6.
    PubMed Google Scholar
  22. Ellem KAO, Orourke MGE, Johnson GR, et al. 1997, A case report: Immune responses and clinical course of the first human use of granulocyte/macrophage-colony-stimulating-factor-transduced autologous melanoma cells for immunotherapy. Cancer Immunol Immunother, 44, 10-20.
    Google Scholar
  23. Kuge S, Miura Y, Nakamura Y, Mitomi T, Habu S and Nishimura T, 1995, Superantigen-induced human CD4+ helper/killer T cell phenomenon. Selective induction of Th1 helper/killer T cells and application to tumor immunotherapy. J Immunol, 154, 1777-85.
    PubMed Google Scholar
  24. Mertens WC, Bramwell VH, Gwadry-Sridhar F, Romano W, Banerjee D and Lala PK, 1992, Effects of indomethacin plus ranitidine in advanced melanoma patients on high-dose interleukin-2. Lancet, 340, 397-8.
    Article PubMed Google Scholar
  25. Evans R, Kamdar SJ, Duffy T and Edison L, 1993, Intratumor gene expression after adoptive immunotherapy in a murine tumor model. J Immunol, 150, 177-84.
    PubMed Google Scholar
  26. Garrity T, Pandit R, Wright MA, Benefield J and Young MRI, 1997, Increased presence of CD34+ cells in the peripheral blood of head and neck cancer patients and their differentiation into CD1a+ cells. Int J Cancer, in press.
  27. Young MRI, Ihm J, Lozano Y, Wright MA and Prechel MM, 1995, Treating tumor-bearing mice with vitamin D3 diminishes tumor-induced myelopoiesis and associated immune suppression, and reduces tumor metastasis and recurrence. Cancer Immunol Immunother, 41, 37-45.
    Article PubMed Google Scholar
  28. Prechel M, Lozano Y, Wright MA, Ihm J and Young MRI, 1996, Immune modulation by interleukin-12 in tumor-bearing mice receiving vitamin D3 treatments to block induction of immune suppressive granulocyte-macrophage progenitor cells. Cancer Immunol Immunother, 42, 213-20.
    Google Scholar
  29. Young MRI, Wright MA, Coogan M, Young ME and Bagash J, 1992, Tumor-derived cytokines induce bone marrow suppressor cells that mediate immunosuppression through transforming growth factor ?. Cancer Immunol Immunother, 35, 14-18.
    PubMed Google Scholar
  30. Inge TH, Hoover SK, Susskind BM, Barrett SK and Bear HD, 1992, Inhibition of tumor-specific cytotoxic T-lymphocyte responses by transforming growth factor b1. Cancer Res, 52, 1386-92.
    PubMed Google Scholar
  31. Alleva DG, Burger CJ and Elgert KD, 1994, Tumor-induced regulation of suppressor macrophage nitric oxide and TNF-α production. Role of tumor-derived IL-10, TGF-β, and prostaglandin E2. J Immunol, 153, 1674-86.
    PubMed Google Scholar
  32. Duits AJ, Dimjati W, van de Winkel JGJ and Capel PJA, 1992, Synergism of interleukin 6 and 1?,25-dihydroxy-vitamin D3 in induction of myeloid differentiation of human leukemic cell lines. J Leuko Biol, 51, 237-43.
    PubMed Google Scholar
  33. van der Hem KG, Drager AM, Huijgens PC, Tol C, Deville W and Langenhuijsen MM, 1994, The differentiation inducing effect of bryostatin 5 on human myeloid blast cells is potentiated by vitamin D3. Leukemia, 8, 266-73.
    PubMed Google Scholar
  34. Testa U, Masciulli R, Tritarelli E, et al. 1993, Transforming growth factor-? potentiates vitamin D3-induced terminal monocytic differentiation of human leukemic cell lines. J Immunol, 150, 2418-30.
    PubMed Google Scholar
  35. Triozzi PL and Aldrich W, 1997, Phenotypic and functional differences between human dendritic cells derived _in vitro_from hematopoietic progenitors and from monocytes/macrophages. J Leuko Biol, 61, 600-8.
    PubMed Google Scholar
  36. Berardi AC, Wang A, Levine JD, Lopez P and Scadden DT, 1995, Functional isolation and characterization of human hematopoietic stem cells. Science, 267, 104-8.
    Google Scholar
  37. Koyama S and Fukao K, 1994, Phenotypic analysis of nylon-wool-adherent suppressor cells that inhibit the effector process of tumour cell lysis by lymphokine-activated killer cells in patients with advanced gastric carcinoma. J Cancer Res Clin Oncol, 120, 240-7.
    PubMed Google Scholar
  38. Akhter J, Goerdel M and Morris DL, 1996, Vitamin D3 analogue (EB 1089) inhibits _in vitro_cellular proliferation of human colon cancer cells. Br J Surg, 83, 229-30.
    Article PubMed Google Scholar
  39. Kawa S, Yoshizawa K, Tokoo M, et al. 1996, Inhibitory effect of 20-oxa-1,25-dihydroxyvitamin D3 on the proliferation of pancreatic cancer cell lines. Gastroenterology, 110, 1605-13.
    Google Scholar
  40. Wali RK, Bissonnette M, Khare S, Hart J, Sitrin MD and Brasitus TA, 1995, 1?,25-Dihydroxy-16-ene-26, 27-hexafluorocholecalciferol, a noncalcemic analogue of 1?,25-dihydroxyvitamin D3, inhibits azoxymethaneinduced colonic tumorigenesis. Cancer Res, 55, 3050-4.
    PubMed Google Scholar

Download references